Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

por Stover, Daniel G., Gil Del Alcazar, Carlos R., Brock, Jane, Guo, Hao, Overmoyer, Beth, Balko, Justin, Xu, Qiong, Bardia, Aditya, Tolaney, Sara M., Gelman, Rebecca, Lloyd, Maxwell, Wang, Yu, Xu, Yaomin, Michor, Franziska, Wang, Vivian, Winer, Eric P., Polyak, Kornelia, Lin, Nancy U.
Publicado 2018

Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer

por Gil Del Alcazar, Carlos R., Trinh, Anne, Alečković, Maša, Rojas Jimenez, Ernesto, Harper, Nicholas W., Oliphant, Michael U.J., Xie, Shanshan, Krop, Ethan D., Lulseged, Bethlehem, Murphy, Katherine C., Keenan, Tanya E., Van Allen, Eliezer M., Tolaney, Sara M., Freeman, Gordon J., Dillon, Deborah A., Muthuswamy, Senthil K., Polyak, Kornelia
Publicado 2022

Breast cancer prevention by short-term inhibition of TGFβ signaling

por Alečković, Maša, Cristea, Simona, Gil Del Alcazar, Carlos R., Yan, Pengze, Ding, Lina, Krop, Ethan D., Harper, Nicholas W., Rojas Jimenez, Ernesto, Lu, Donghao, Gulvady, Anushree C., Foidart, Pierre, Seehawer, Marco, Diciaccio, Benedetto, Murphy, Katherine C., Pyrdol, Jason, Anand, Jayati, Garza, Kodie, Wucherpfennig, Kai W., Tamimi, Rulla M., Michor, Franziska, Polyak, Kornelia
Publicado 2022